TreatSMA

APPG on Access to Medicines and Medical Devices – NICE Methods Review Report

Recently there has been a drive from various stakeholders involved in how new medicines or medical devices gain access to the UK market to introduce changes that reflects modern needs of the country. This drive for change generated discussions and some recommendations on how National Institute for Health and Care Excellence should operate in the future. Amongst many important recommendations one is putting greater emphasis on Real World Evidence (RWE), something that TreatSMA has constantly campaigned about and pushed during the Spinraza Appraisal.

The changes and reviewed offered by APPG on Access to Medicines and Medical Devices is welcomed by TreatSMA as a positive step forward.

Click here to read the full report.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more